«Excitement in the brown fat field has risen significantly over last few years because its energy - burning nature makes it a potential therapeutic
target against obesity and diabetes,» said Dr Lee.
Not exact matches
Media Statement 9 October, 2015 New campaign
against soft drinks fails to tackle real health challenges Responding to the «Rethink Sugary Drink» campaign, which
targets sugar - sweetened drink consumption and its purported impact on health, Geoff Parker, Australian Beverages Council CEO, states: «Continuing to vilify soft drinks as a leading cause of
obesity is distorting the -LSB-...]
The findings could offer scientists a new
target for developing drugs
against obesity and other appetite - related disorders, the researchers say.
«Together, our findings indicate that these molecular regulators, TRIP - Br2 and GATA3, could be viable
targets for small drug molecules that could serve as potential therapeutic agents
against obesity,» Liew said.
There is no easy answer in our ongoing battle
against obesity, but identifying the link between the drop in physical activity and increased BMIs, as well as the groups particularly affected, can assist public health officials to develop
targeted, effective interventions.
Preliminary genetic evidence included in the study suggests that the enzyme, called SNRK, performs similar functions in humans, making it an intriguing new drug
target in the battle
against obesity and its complications.
«If we can come up with strategies to carefully
target fat cells, then I think activating this pathway could be effective in the fight
against obesity,» he says.
Therefore, this complex is a highly promising therapeutic drug
target against diabetes,
obesity, Wolff - Parkinson - White Syndrome, cancer, and aging.
The increase in intracellular NAD elicited by CD38 deletion significantly activated SIRT1 and prompted clinical phenotypes similar to those expected for SIRT1 activation, including protection
against diet - induced
obesity and a robust deacetylation of SIRT1
targets.